On-demand dosing with ALPROLIX®
Pediatric and adult/adolescent dosing targets for on-demand treatment and control of bleeding episodes1
Type of bleed
Target circulating factor IX
(IU/dL or % of normal)
Minor and moderatea
Repeat every 48 hours if there is further evidence of bleeding
Consider a repeat dose after 6-10 hours and then every 24 hours for the first 3 days
Due to the long half-life of ALPROLIX, the dose may be reduced and the frequency of dosing may be extended after Day 3 to every 48 hours or longer until bleeding stops and healing is achieved
aMinor and moderate bleed events. For example: uncomplicated hemarthroses, superficial muscle (except iliopsoas) without neurovascular compromise, superficial soft tissue, mucous membranes.
bMajor bleed events. For example: iliopsoas and deep muscle with neurovascular injury or substantial blood loss; pharyngeal, retropharyngeal, retroperitoneal, CNS.
Clinical trial information
B-LONG was a phase 3 open-label study that investigated the safety and efficacy of ALPROLIX in 123 previously treated adult and adolescent patients aged ≥12 years with severe hemophilia B. The study included a fixed-interval (weekly) arm (n=63), a fixed-dose (interval-adjusted) arm (n=29), an episodic (on-demand) arm (n=27), and a surgical arm (n=12).2
B-YOND was an extension trial that studied the long-term safety and efficacy of ALPROLIX in 120 adult, adolescent, and pediatric patients previously treated in Kids B-LONG or B-LONG. The study included a fixed-interval arm (n=74), a fixed-dose arm (n=36), a modified prophylaxis arm (n=17), and an episodic (on-demand) arm (n=15).4